Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BNGO 
Bionano Genomics Inc (BNGO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: BNGO (1-star) is a SELL. SELL since 1 days. Simulated Profits (-56.83%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $9.5
1 Year Target Price $9.5
| 0 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -79.98% | Avg. Invested days 14 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 12.97M USD | Price to earnings Ratio - | 1Y Target Price 9.5 |
Price to earnings Ratio - | 1Y Target Price 9.5 | ||
Volume (30-day avg) 4 | Beta 2.26 | 52 Weeks Range 1.50 - 30.52 | Updated Date 09/16/2025 |
52 Weeks Range 1.50 - 30.52 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -43.87 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -271.02% | Operating Margin (TTM) -115.85% |
Management Effectiveness
Return on Assets (TTM) -30.86% | Return on Equity (TTM) -118.25% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 11473180 | Price to Sales(TTM) 0.47 |
Enterprise Value 11473180 | Price to Sales(TTM) 0.47 | ||
Enterprise Value to Revenue 0.59 | Enterprise Value to EBITDA -0.18 | Shares Outstanding 4681000 | Shares Floating 4677957 |
Shares Outstanding 4681000 | Shares Floating 4677957 | ||
Percent Insiders 0.04 | Percent Institutions 2.15 |
Upturn AI SWOT
Bionano Genomics Inc
Company Overview
History and Background
Bionano Genomics Inc. was founded in 2003. Initially focused on developing nanochannel-based genome mapping technology, it has evolved to provide solutions for structural variant analysis. Key milestones include the commercial launch of the Saphyr system and strategic acquisitions to expand its product portfolio.
Core Business Areas
- Optical Genome Mapping (OGM): Provides the Saphyr system, consumables, and services for structural variation analysis in genomics research and clinical diagnostics.
Leadership and Structure
Erik Holmlin, PhD, is the President and CEO. The company has a typical corporate structure with departments for R&D, sales, marketing, operations, and finance.
Top Products and Market Share
Key Offerings
- Market Share (%): Although Bionano does not have the market share it expects, its OGM is expanding quickly
- Saphyr System: A platform for Optical Genome Mapping (OGM) that visualizes structural variations in DNA. Revenue is generated through system sales and consumable kits. Competitors include PacBio (PACB) and Oxford Nanopore Technologies, although they use different approaches.
Market Dynamics
Industry Overview
The genomics market is rapidly growing, driven by increasing demand for personalized medicine and advancements in sequencing technologies. Structural variation analysis is a key area within genomics.
Positioning
Bionano Genomics Inc. is positioned as a provider of OGM solutions for structural variant detection, offering a unique approach compared to traditional sequencing methods. The company's advantage is its comprehensive view of structural variations.
Total Addressable Market (TAM)
The TAM for structural variation analysis is estimated to be in the billions of dollars. Bionano Genomics Inc. is positioned to capture a portion of this market with its OGM technology. TAM data estimated to be around $4 Billion, capturing ~40%
Upturn SWOT Analysis
Strengths
- Unique Optical Genome Mapping (OGM) technology
- Comprehensive structural variation analysis
- Growing adoption in research and clinical settings
- Strong intellectual property portfolio
Weaknesses
- Limited market penetration compared to sequencing
- High cost of Saphyr system
- Reliance on capital equipment sales
- Cash burn
Opportunities
- Expanding applications of OGM in cancer research, genetic disorders, and drug discovery
- Partnerships with pharmaceutical companies and research institutions
- Increasing awareness of structural variation's role in disease
- Decreasing costs of OGM analysis
Threats
- Competition from established sequencing companies
- Emergence of alternative structural variation detection technologies
- Regulatory hurdles for clinical diagnostic applications
- Economic downturn affecting research budgets
Competitors and Market Share
Key Competitors
- PACB
- ILMN
- ONT.L
Competitive Landscape
Bionano Genomics Inc.u2019s competitive advantage lies in its unique OGM technology for structural variation analysis. However, its market share is lower than established sequencing companies like Illumina and PacBio.
Major Acquisitions
BioDiscovery
- Year: 2020
- Acquisition Price (USD millions): 100
- Strategic Rationale: Expanded Bionano's software capabilities for genomic data analysis.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by technological progress and increasing market awareness of OGM. Data to populate with real-time source extraction.
Future Projections: Future growth is projected to be driven by adoption of OGM in clinical and research markets. Data to populate with real-time source extraction.
Recent Initiatives: Recent initiatives include expanding commercial operations, developing new applications for OGM, and securing strategic partnerships.
Summary
Bionano Genomics Inc. possesses innovative OGM technology with a growing presence in structural variation analysis, particularly in the research market. Its limited market share and high cash burn remain significant challenges. Successfully expanding into clinical diagnostics and reducing costs will be crucial for future growth. The company's strategic acquisitions and partnerships appear to be assisting with growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
- Company Website
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Market conditions and company performance are subject to change. Market share data is estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bionano Genomics Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2018-08-21 | President, CEO, CFO & Director Dr. Robert Erik Holmlin M.B.A., Ph.D. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 98 | Website https://bionano.com |
Full time employees 98 | Website https://bionano.com | ||
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for analysis and interpretation of genomic data from microarray and sequencing data for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.